Hi, my name is Hun-Jae Cho. I'm an associate professor of medicine at the Multiple Myeloma Center of Excellence at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York City. I'm also the chief medical officer for the Multiple Myeloma Research Foundation. This ASH meeting has shown us incredible developments in novel immune therapies for multiple myeloma and new targeted therapies against multiple myeloma. And in this dizzying array of new agents and new treatment strategies, there's an increased sense of optimism, as well there should be. And yet today in 2022, we still do not have broadly applicable curative therapy for multiple myeloma. In addition, there's a lot of questions about what the safest and best way to apply these powerful new immunotherapies, where does that lie in the treatment scheme for multiple myeloma? So there's an urgent need for new types of clinical trial strategies in order to rapidly test different types of dosing schedules, different combinations of agents. And this is to determine the best way to apply these powerful technologies. I think that there's a heightened acceptance of innovative trial designs, for example, adaptive platform trials that will allow you to test a multiple different treatment strategies in one clinical trial that would give you the ability to add or subtract different sub protocols rapidly to respond to a changing landscape in multiple myeloma. And we at the MMRF are engaged in this type of effort. We're launching a series of platform trials in high risk, newly diagnosed multiple myeloma and in relapsed refractory multiple myeloma after CD38 and BCMA directed therapies. And a number of other research consortia and other pharma partners are also adapting similar platform trial strategies in order to accelerate progress towards curative therapy in multiple myeloma.
HealthTree • May 1, 2023